During the MPN Hub Steering Committee meeting featuring John Mascarenhas, Steffen Koschmieder, Laura Michaelis, and Tiziano Barbui, Ruben Mesa discussed the use of momelotinib and luspatercept for the treatment of patients with myelofibrosis and anemia. This educational resource is independently supported by GSK and Bristol Myers Squibb. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource. Hosted o...
May 19, 2025•32 min
This educational resource is independently supported by GSK. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource. During the European School of Haematology (ESH) 4th How to Diagnose and Treat: CML/MPN conference, the MPN Hub hosted a symposium titled “Anemia in myelofibrosis: Sequencing therapies to optimize patient outcomes.” The symposium closed with a panel Q&A session with live audience par...
May 12, 2025•15 min
This independent educational activity is supported by GSK. All content is developed independently by the faculty; the funder is allowed no influence on the content. During the European School of Haematalogy (ESH) 4th How to Diagnose and Treat CML/MPN conference, the MPN hub held a symposium on March 9, 2025, titled, Anemia in myelofibrosis: Sequencing therapies to optimize patient outcomes. Here, we share a presentation by Paola Guglielmelli, University of Florence, Florence, IT, discussing th...
May 08, 2025•16 min
This independent educational activity was supported by GSK. All content was developed independently by the faculty; the funder is allowed no influence on the content. During the European School of Haematalogy (ESH) 4th How to Diagnose and Treat CML/MPN conference, the MPN Hub held a symposium on March 9, 2025, titled Anemia in myelofibrosis: Sequencing therapies to optimize patient outcomes. Here, we share a presentation by Francesco Passamonti, Università degli Studi di Milano, Milan, IT, disc...
May 07, 2025•15 min
This educational resource is independently supported by GSK. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource. During an MPN Hub symposium presented at the European School of Haematology (ESH) 4th How to Diagnose and Treat: CML/MPN conference, MPN Hub steering committee Chair Jean-Jacques Kiladjian, Université Paris Cité and Hôpital Saint-Louis, Paris, FR, presented a review of anemia in myelofi...
May 06, 2025•7 min
During the MPN Hub Steering Committee meeting, Ruben Mesa discussed anemia as an unmet need and the impact on quality of life and survival outcomes in patients with myelofibrosis (MF). Key points Anemia in patients with MF is a complex, multifactorial process, and can be exacerbated by treatment with some Janus kinase inhibitors, including ruxolitinib and fedratinib . Anemia is common in patients with primary MF, with one study reporting hemoglobin levels <10 g/dL in 38% of patients at the ti...
Apr 29, 2025•12 min
The MPN Hub was pleased to speak to Aaron Gerds, Cleveland Clinic Taussig Cancer Institute, Cleveland, US. Gerds discussed treating anemia in patients with myelofibrosis (MF). Gerds highlights the impact of anemia on survival outcomes in patients with MF, and reviews key data from the phase II ACE-536-MF-001 trial (NCT03194542) evaluating the safety and efficacy of luspatercept in patients with MF and anemia, including patients with and without transfusion dependence and concurrent Janus kinase ...
Mar 26, 2025•7 min
The MPN Hub was pleased to speak to Aaron Gerds, Cleveland Clinic Taussig Cancer Institute, Cleveland, US. We asked, How might luspatercept benefit patients with myelofibrosis (MF)? Aaron Gerds opens by discussing the prevalence and issue of anemia in patients with MF, noting that almost all patients will become anemic at some point in the course of their disease. Gerds discusses luspatercept as a treatment option in this indication, sharing the latest clinical trial data and emphasizing the ben...
Sep 12, 2024•8 min
During the European Hematology Association (EHA) 2024 Hybrid Congress, the MPN Hub was pleased to speak with Haifa Kathrin Al-Ali, University Hospital Halle, Halle, DE. We asked, What more can be done to improve treatment for patients with polycythemia vera? Al-Ali provides an overview of how to improve treatment and outcomes for patients with polycythemia vera, opening with a discussion of the latest advancements in the field and key areas for improvement. Al-Ali shares insights on symptoms man...
Aug 09, 2024•6 min
The MPN Hub was pleased to speak to Laura Michaelis, Medical College of Wisconsin, Milwaukee, US and Anand Patel, University of Chicago, Chicago, US. We asked, When to refer patients with MPN to clinical trials: Part II - Patients with myelofibrosis (MF). Patel opens by highlighting the need for more long-term effective MF treatments and presents long-term data on the cessation of existing therapies such as ruxolitinib. Michaelis and Patel then discuss factors that influence the decision to refe...
Mar 06, 2023•15 min•Ep. 2
The MPN Hub was pleased to speak to Laura Michaelis, Medical College of Wisconsin, Milwaukee, US and Anand Patel, University of Chicago, Chicago, US. We asked, When to refer patients with MPN to clinical trials: Part I — Patients with essential thrombocytopenia/polycythemia vera. In this podcast, Michaelis and Patel discuss the factors which determine whether standard of care treatment or referral to a clinical trial is the most appropriate course of action. Patel begins by outlining drugs curre...
Mar 02, 2023•12 min•Ep. 1
During the 63rd ASH Annual Meeting and Exposition, the MPN Hub was pleased to speak to Laura Michaelis (Medical College of Wisconsin, Milwaukee, US) and Claire Harrison (Guy's and St Thomas' NHS Foundation Trust, London, UK). We asked, Patient follow-up in myeloproliferative neoplasms: Best practices and myths. In this podcast, Michaelis and Harrison discuss the best practices in MPN, in particular in regards to diagnosis. They also discuss the new data that was presented at ASH 2021, such as th...
Feb 04, 2022•14 min•Ep. 7
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub spoke to Marina Kremyanskaya, Icahn School of Medicine at Mount Sinai, New York, US. We asked, Is the hepcidin-mimetic PTG‑300 a promising treatment for therapeutic phlebotomy-dependent polycythemia vera (PV)? Currently, patients with PV require frequent phlebotomy. Kremyanskaya discusses promising results from a phase II clinical trial evaluating the safety and efficacy of PTG-300, a novel hepcidin-m...
Feb 03, 2021•8 min
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub spoke to Jyoti Nangalia, University of Cambridge, Cambridge, UK. We asked, Should we consider early testing and treatment for driver mutations acquired in childhood? In this podcast, Jyoti Nangalia reports results from a study using next-generation sequencing to trace acquired MPN mutations in hematopoietic stem cells taken from patients with varying stages of disease presentation. Nangalia discusses ...
Jan 28, 2021•6 min
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub spoke to the Steering Committee Chair, Jean-Jacques Kiladjian, Université de Paris, Paris, FR. We asked, When can we safely discontinue interferon alpha therapy in patients with myeloproliferative neoplasms? Results from several studies have shown that interferon alpha is able to induce high rates of complete hematological remission in patients with polycythemia vera, but what are the outcomes in pati...
Dec 17, 2020•5 min
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub spoke to Ghaith Abu-Zeinah, Weill Cornell Medicine, New York, US. We asked, Does interferon alpha prolong survival and prevent progression in patients with polycythemia vera (PV)? PV is a disease associated with shorter survival due to short-term complications, such as thrombosis, and long-term complications of progression to myelofibrosis and transformation to acute leukemia, which are associated wit...
Dec 15, 2020•6 min•Ep. 1
During the First Annual Texas Virtual MPN Workshop, the MPN Hub spoke to our Steering Committee members Laura Michaelis, Medical College of Wisconsin, Milwaukee , US, and Tiziano Barbui, Papa Giovanni XXIII Hospital, Bergamo, IT. We asked, What do we know about the outcome of concomitant MPN and COVID-19? In this podcast, Tiziano Barbui starts by giving some background to the COVID-19 pandemic in Europe. Prof. Barbui has focused on how to help his patients with myeloproliferative neoplasms (MPN)...
Nov 06, 2020•18 min
During the American Association of Cancer Research (AACR) Virtual Annual Meeting I, the MPN Hub was pleased to speak to Christine Spencer, Parker Institute for Cancer Immunotherapy, San-Francisco, US and Diwakar Davar, University of Pennsylvania Medical Center, Pittsburgh, US. We asked: how can we use the microbiome to improve cancer immunotherapy and alleviate side effects such as graft- versus -host-disease? In this podcast, Dr Davar starts by providing a background on the importance of the mi...
Jun 30, 2020•25 min
